From the Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Maryland.
From the Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Maryland.
J Heart Lung Transplant. 2024 Jan;43(1):77-84. doi: 10.1016/j.healun.2023.06.016. Epub 2023 Jun 30.
Extracorporeal membrane oxygenation (ECMO) is increasingly relied on to bridge patients with respiratory failure to lung transplantation despite limited evidence for its use in this setting. This study evaluated longitudinal trends in practice patterns, patient characteristics, and outcomes in patients bridged with ECMO to lung transplant.
A retrospective review of all adult isolated lung transplant patients in the United Network for Organ Sharing database between 2000 and 2019 was performed. Patients were classified as "ECMO" if supported with ECMO at the time of listing or transplantation and "non-ECMO" otherwise. Linear regression was used to evaluate trends in patient demographics during the study period. Trends in mortality were evaluated using Cox proportional hazards modeling, with time period as the primary covariate (2000-2004, 2005-2009, 2010-2014, or 2015-2019) and age, time on the waitlist, and underlying diagnosis as covariates.
The number of patients included were 40,866, of whom 1,387 (3.4%) were classified as ECMO and 39,479 (96.6%) as no ECMO. Average age and initial Lung Allocation Score increased significantly during the study period in both cohorts, but occurred at a slower rate in the ECMO population. The hazard of death was significantly lower in more recent years (2015-2019) for both the ECMO and non-ECMO cohorts (aHR (adjusted hazards ratio) 0.59, 95% confidence interval (CI) 0.37-0.96 and aHR 0.74, 95% CI 0.70-0.79) when compared to the early years (2000-2004) of the study period.
Post-transplantation survival for patients bridged to transplantation with ECMO demonstrates ongoing improvement despite cannulation of progressively older and sicker patients.
尽管在这种情况下使用体外膜肺氧合(ECMO)的证据有限,但 ECMO 越来越多地被用于桥接呼吸衰竭患者进行肺移植。本研究评估了在接受 ECMO 桥接肺移植的患者中,实践模式、患者特征和结局的纵向趋势。
对 2000 年至 2019 年间美国器官共享网络数据库中所有接受孤立性肺移植的成年患者进行了回顾性分析。如果患者在列入名单或移植时接受 ECMO 支持,则将其归类为“ECMO”,否则归类为“非 ECMO”。使用线性回归评估研究期间患者人口统计学特征的趋势。使用 Cox 比例风险模型评估死亡率趋势,时间范围为主要协变量(2000-2004 年、2005-2009 年、2010-2014 年或 2015-2019 年),年龄、等待名单上的时间和基础诊断为协变量。
共纳入 40866 例患者,其中 1387 例(3.4%)归类为 ECMO,39479 例(96.6%)归类为非 ECMO。在两个队列中,研究期间患者的平均年龄和初始肺分配评分均显著增加,但在 ECMO 人群中增加速度较慢。与研究早期(2000-2004 年)相比,近年来(2015-2019 年)ECMO 和非 ECMO 队列的死亡风险均显著降低(调整后的危险比(aHR)分别为 0.59,95%置信区间(CI)为 0.37-0.96 和 aHR 0.74,95%CI 0.70-0.79)。
尽管对越来越老和病情越来越严重的患者进行 ECMO 插管,但接受 ECMO 桥接移植的患者的移植后生存率仍在不断提高。